- Home
- AVBP vs NXP Comparison
AVBP vs NXP Comparison
Compare AVBP & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- NXP
- Stock Information
- Founded
- AVBP 2021
- NXP 1992
- Country
- AVBP United States
- NXP United States
- Employees
- AVBP N/A
- NXP N/A
- Industry
- AVBP
- NXP Trusts Except Educational Religious and Charitable
- Sector
- AVBP
- NXP Finance
- Exchange
- AVBP NYSE
- NXP Nasdaq
- Market Cap
- AVBP 705.8M
- NXP 730.9M
- IPO Year
- AVBP 2024
- NXP N/A
- Fundamental
- Price
- AVBP $25.22
- NXP $13.96
- Analyst Decision
- AVBP Strong Buy
- NXP
- Analyst Count
- AVBP 7
- NXP 0
- Target Price
- AVBP $39.29
- NXP N/A
- AVG Volume (30 Days)
- AVBP 377.5K
- NXP 70.0K
- Earning Date
- AVBP 08-13-2025
- NXP 01-01-0001
- Dividend Yield
- AVBP N/A
- NXP 4.04%
- EPS Growth
- AVBP N/A
- NXP N/A
- EPS
- AVBP N/A
- NXP 0.54
- Revenue
- AVBP N/A
- NXP N/A
- Revenue This Year
- AVBP $66.25
- NXP N/A
- Revenue Next Year
- AVBP N/A
- NXP N/A
- P/E Ratio
- AVBP N/A
- NXP $26.81
- Revenue Growth
- AVBP N/A
- NXP N/A
- 52 Week Low
- AVBP $15.47
- NXP $12.91
- 52 Week High
- AVBP $36.37
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- AVBP 67.19
- NXP 45.32
- Support Level
- AVBP $22.65
- NXP $13.95
- Resistance Level
- AVBP $25.80
- NXP $14.08
- Average True Range (ATR)
- AVBP 1.32
- NXP 0.11
- MACD
- AVBP 0.18
- NXP -0.00
- Stochastic Oscillator
- AVBP 87.89
- NXP 34.60
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.